R Squared’s Standard BioTools LAB Stock Holding History

R Squared’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,268	Closed	-$9.44K	–	622
2026 Q1	$9.44K	Buy	+10,268	New	+$12.4K	0.01%	471
2025 Q3	–	Sell	-12,947	Closed	-$15.5K	–	641
2025 Q2	$15.5K	Buy	+12,947	New	+$14.4K	0.01%	450

Other funds holding LAB

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

R Squared's LAB Position: Q2 2026 in Review

R Squared sold out of Standard BioTools (LAB) in Q2 2026, closing a stake of 10,268 shares — an estimated $9.44K sold.

R Squared first reported a position in LAB in Q2 2025 and held it in 2 quarters. The position peaked at $15.5K in Q2 2025. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

R Squared reported no remaining Standard BioTools position as of Q2 2026 after selling out during the quarter.
R Squared sold 10,268 Standard BioTools shares in Q2 2026, an estimated $9.44K.
R Squared first reported a position in Standard BioTools in Q2 2025 and held it in 2 quarters.
R Squared's Standard BioTools position peaked at $15.5K in Q2 2025.
143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on R Squared's 13F filing for Q2 2026, filed 5 Aug 2026.